Byrne, B., Bratkovic, D., Díaz-Manera, J., Laforêt, P., Mozaffar, T., van der Ploeg, A., … Kishnani, P. S. (2022). Cipaglucosidase alfa/miglustat versus alglucosidase alfa/placebo in late-onset Pompe disease (LOPD): PROPEL study subgroup analyses. In Molecular Genetics and Metabolism (Vol. 135, pp. S27–S28). Elsevier BV. https://doi.org/10.1016/j.ymgme.2021.11.054

Byrne, Barry, Drago Bratkovic, Jordi Díaz-Manera, Pascal Laforêt, Tahseen Mozaffar, Ans van der Ploeg, Mark Roberts, et al. “Cipaglucosidase alfa/miglustat versus alglucosidase alfa/placebo in late-onset Pompe disease (LOPD): PROPEL study subgroup analyses.” In Molecular Genetics and Metabolism, 135:S27–28. Elsevier BV, 2022. https://doi.org/10.1016/j.ymgme.2021.11.054.

Byrne B, Bratkovic D, Díaz-Manera J, Laforêt P, Mozaffar T, van der Ploeg A, et al. Cipaglucosidase alfa/miglustat versus alglucosidase alfa/placebo in late-onset Pompe disease (LOPD): PROPEL study subgroup analyses. In: Molecular Genetics and Metabolism. Elsevier BV; 2022. p. S27–8.

Byrne, Barry, et al. “Cipaglucosidase alfa/miglustat versus alglucosidase alfa/placebo in late-onset Pompe disease (LOPD): PROPEL study subgroup analyses.” Molecular Genetics and Metabolism, vol. 135, no. 2, Elsevier BV, 2022, pp. S27–28. Crossref, doi:10.1016/j.ymgme.2021.11.054.

Byrne B, Bratkovic D, Díaz-Manera J, Laforêt P, Mozaffar T, van der Ploeg A, Roberts M, Schoser B, Toscano A, Jiang H, Sitaraman S, Goldman M, Castelli J, Kishnani PS. Cipaglucosidase alfa/miglustat versus alglucosidase alfa/placebo in late-onset Pompe disease (LOPD): PROPEL study subgroup analyses. Molecular Genetics and Metabolism. Elsevier BV; 2022. p. S27–S28.